Welcome to our dedicated page for Astria Therapeutics news (Ticker: $ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astria Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astria Therapeutics's position in the market.
Astria Therapeutics, a biopharmaceutical company, will be presenting information on STAR-0310 at the Society for Investigative Dermatology Annual Meeting. The presentation will focus on the preclinical profile of a novel OX40 antagonistic monoclonal antibody. Dr. Chunxia Lily Zhao will present the poster at the event in May 2024.
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 173,500 shares of common stock under the 2022 Inducement Stock Incentive Plan to new employees. The options have an exercise price of $9.50, vesting over four years, with 25% vesting after one year and the rest monthly over 36 months, contingent on continued employment.
